Start a Conversation
← All Success Stories
Success Story · Biotech · Private Equity-Backed

Growth at the Pace of Private Equity

ImmunoTek

2020 – Present

Company Overview

Industry
Plasma & Biotech
Founded
2012
Engagement
Executive Coaching · Org Design · Culture

A purpose-driven biotech, scaling at investor pace.

Founded in 2012, ImmunoTek Bio Centers is a biotech company committed to safely collecting high-quality blood plasma from the public and supplying it to the world’s research, medical supply, and fractionator organizations.
ImmunoTek also specializes in constructing, opening, FDA/EU licensing, and managing multiple plasma collection centers and plasma supply contracts to meet ongoing demand in the plasma proteins therapeutics market in partnership with well-known pharmaceutical companies. The ImmunoTek leadership team brings nearly 100 years of combined experience in the blood, plasma, and biopharma industries.

Introduction

When new capital came in, the bar moved up.

In 2020, ImmunoTek took on a private equity investor, and with that investment came increased expectations around rapid scale. CEO Jerome Parnell III enlisted FMG Leading to help focus the growth strategy, build his personal leadership skills, and redesign the management team structure. Subsequently, FMG Leading began working with several executive team leaders, allowing them to elevate in their roles and focus on the journey ahead.

Partnership

From the boardroom outward — aligned, by design.

ImmunoTek started their partnership with FMG Leading through executive coaching and advising for Jerome and the Board, ensuring clear lines of communication were in place and that the Board was aligned with the strategic direction the firm would take. The partnership then expanded into a series of executive team sessions, which refined the company’s value chain and go-to-market position.

During these sessions, ImmunoTek senior leaders aligned around critical strategic priorities, company values, culture, growth strategy, and future vision. In 2022 the FMG Leading team began coaching several other senior ImmunoTek leaders, completed a culture audit, facilitated a company-wide values refresh and roll-out, and designed and facilitated the company’s first annual National Leadership Meeting (NLM).
  • Executive coaching & advising
  • Board alignment
  • Value-chain refinement
  • Culture audit & values refresh
  • Org & management redesign
  • National Leadership Meeting

Outcomes

Alignment, turned into a number.

Building leader, team, and organizational alignment translated into measurable, durable business results — across scale, scope, and capital structure.

2×

Annual Scale

New plasma collection centers per year grew from under 10 to over 20.

23

Centers Opened

In 2022 alone — the most of any independent plasma organization in a single year.

+51%

Revenue Growth

Year-over-year revenue grew approximately 51% between 2021 and 2022.

$500M+

Annual Revenue

New pharma contracts more than doubled annual revenue past the half-billion mark.

Ongoing Success

The work continues — and so does the growth.

With its leadership bench deepened and a re-energized culture firmly in place, ImmunoTek attracted a new round of capital investment in 2023 with a new majority owner — and continues to operate at the pace and ambition private equity demands.

FMG Leading remains engaged across executive coaching, leadership development, and annual culture and team activation work — supporting Jerome and his team as they enter the next chapter of growth and prepare future leaders for elevated roles.

2023

New majority owner

A second round of capital investment with a new majority owner.

2024

Continued executive coaching

Coaching expanded to additional senior leaders preparing to step into elevated roles.

2025

Third annual National Leadership Meeting

Year-three NLM continues to align the senior team on values, culture, and strategy.

In Their Words

“

Our partnership with FMG Leading helped us merge the old with the new, allowing us to grow into a place where our executive team was aligned and moving in lock-step with our board and advancing the company forward in a very healthy and proactive way.

Picture of Jerome Parnell III

Jerome Parnell III

CEO and Founder, ImmunoTek

Recapitalization Results

Next Story

Florida Gulf-to-Bay

Recapitalization Results

When MTS Health Partners re-capitalized Florida Gulf-to-Bay Anesthesiology Associates and founded Florida Gulf to Bay Holdings, FMG Leading was brought in to assess organizational development and provide the activation support that accelerated growth post-close.
Read the next story

Translate Strategy into Success

One conversation.
One engagement.

Test our integrated model on the strategy you’re being asked to execute right now. Surface the intelligence. Pressure-test the playbook. Align the leadership team. See what an optimized, high-performance organization can actually deliver.
Schedule a Conversation →
Download Firm Overview